ALK and non-small cell lung carcinoma: For example, despite better control of intracranial disease in patients with ALK-rearranged NSCLC treated with second-generation anaplastic lymphoma kinase (ALK) inhibitors (for example, ceritinib and alectinib), relapse with central nervous system (CNS) progression during therapy remains common26,27.